COMP <GO>
MDT vs MRK // REVENUE GROWTH (YOY)
Medtronic plc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MDT 5
— MRK 9
▲ REVENUE GROWTH (YOY) LEADER: MDT
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
revenue-growth
8.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.00% | 74.80% | -9.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 20.70% | -12.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 15.3x | +2.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 3.42% | +0.95 | MDT | /fcf-yield <GO> |
| Operating Margin | 17.80% | 34.30% | -16.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 8.40% | 1.30% | +7.10 | MDT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.93% | 2.26% | +0.67 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.08 | 5.19 | -2.11 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.5 | 56.9 | +3.68 | MDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 18.4x | +121.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $124.22B | $361.02B | -$236.80B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDT REV | MRK REV | MDT GROSS % | MRK GROSS % | MDT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | $65.01B | 65.0% | 74.8% | $5.43B | $12.36B |
| FY 2024 | $33.54B | $64.17B | 65.3% | 76.3% | $5.18B | $18.10B |
| FY 2023 | $32.36B | $60.12B | 44.0% | 44.0% | $5.33B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDT // BETA 0.91
MRK // BETA 0.92